NASDAQ:TRDA | Free Cash Flow | Entrada Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$41.7M$44,000.00-$41.74M
2025-12-31-$32.2M-$207,000.00-$32.41M
2025-03-31-$38.51M$1.14M-$39.65M
2024-12-31-$31.61M$635,000.00-$32.24M-2850.57%
2024-03-31-$25.52M$838,000.00-$26.36M-112.18%
2023-12-31-$4.01M$976,000.00-$4.99M
2023-03-31$203.4M$1.67M$201.73M
2022-12-31-$27.3M$708,000.00-$28.01M
2022-03-31-$20.99M$594,000.00-$21.59M
2021-12-31-$20.54M$1.32M-$21.86M
2021-03-31-$8.34M$908,000.00-$9.24M
2020-12-31-$6.62M$1.44M-$8.07M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$128.51M$1.04M-$129.55M
2024-12-31-$41.56M$3.16M-$44.72M-68.14%
2023-12-31$139.8M$5.61M$134.19M
2022-12-31-$93.79M$2.89M-$96.67M
2021-12-31-$50.86M$4.58M-$55.44M
2020-12-31-$25.57M$2.32M-$27.89M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.